STRUCTURE, EFFICACY AND ECONOMY OF THE THERAPY OF HYPERTENSION IN SLOVAK OUT-WARD PATIENTS WITH METABOLIC SYNDROME – PROJECT NEMESYSRNRN
Topic: | |
Type: Poster - doctors , Number in the programme: 52 | |
Lietava J.1, Kosmálová V.1, Čaprnda M.1, Turek P.2, Fodor G.3 1 II.interná klinika, Fakultná nemocnice, Bratislava, SR, 2 ., 3 Heart Institute, University of Ottawa, Ottawa, Canada | |
Introduction. Increased blood pressure is one of discriminant criteria for presence of metabolic syndrome (MS). Despite of numerous analyses of antihypertensive therapy, its evaluation in association to MS are seldom. Method: Crosssectional multicentric screening of MS and structure of medication was performed in 8679 consequetive out-ward patients in whole territory of Slovakia. MS was defined according to IDF criteria (IDF 2005). Results. Out-ward patients aged 52.4±16.1 yrs [17-96 yrs] exhibited 25.6% prevalence of MS (23.7% in males; 26.9% in females; p<0.01). Hypertension (BP≥140/90 mmHg) or antihypertensive therapy were present in 65.8% pts. Target blood pressure for MS [BP <130/85 mm Hg] was reached in 13.3% of MS+ pts and 14.7% of MS- of treated hypertensive patients (NS). MS + pts were more often unsuccessfully treated (70.1% vs. 54.4%; p<0.001). Both subgroups had similar structure of therapy, however, MS+ pts were treated more expensively – antihypertensive therapy was 14.9 vs 13.1 SK of DDD (p<0.001); hypolipodemic therapy was 12.3 vs 10.7 SK of DDD (p<0.001); and whole therapy was 34.7 vs 30.3 SK of DDD (p<0.01). Conclusion: Project NEMESYS found 25.6% prevalence of metabolic syndrom between out-ward patients. Their antihypertensive and hypolipidemic therapies were more expensive and equally efficient (resp. non.efficient) in comparison with patients without MS. Only 14% of pts reached normotension. | |